title: Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure.
abstract: OBJECTIVE
  To determine the efficacy of partial cryoablation of the prostate in the salvage setting.
  
  
  METHODS
  All patients who were treated between April 2004 and September 2007 for recurrent prostate adenocarcinoma after failure of primary radiotherapy by means of partial cryoablation were identified.
  
  
  RESULTS
  Nineteen patients met inclusion criteria; 15 had >6 months' follow-up. Mean age was 71 years. Men received salvage therapy a mean of 6 years after primary radiotherapy. Median follow-up was 18 months (range, 6-33 months). The biochemical recurrence-free survival rate (according to the American Society for Therapeutic Radiology and Oncology definition) was 89%, 67%, and 50% at 1, 2, and 3 years, respectively. One of 10 patients harbored residual carcinoma on routine follow-up biopsy at 1 year, whereas 50% harbored residual benign prostate tissue. Complications included incontinence (1), urethral stricture (1), and urethral ulcer (1).
  
  
  CONCLUSIONS
  In properly selected patients with a unilateral focus of disease recurrence after radiotherapy, acceptable oncologic results can be achieved with partial cryoablation of the prostate, with low morbidity.
authors.affiliation: Department of Urology, University of California-San Francisco, San Francisco, California 94143-1695, USA. eisenbergm@urology.ucsf.edu
authors.forename: Michael L
authors.initials: ML
authors.lastname: Eisenberg
authors.forename: Katsuto
authors.initials: K
authors.lastname: Shinohara
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000532:radiotherapy* / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D003452:Cryosurgery / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000532:radiotherapy* / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen